Metabolism

Bi
Lab scene illustrating breakthrough oral drug enhancing muscle metabolism for type 2 diabetes and obesity, with pill, muscle model, and positive trial graphs.
Hoton da AI ya samar

Oral β2-agonist targeting muscle metabolism shows promise for type 2 diabetes and obesity

An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya

Researchers at Karolinska Institutet and Stockholm University have developed an experimental oral drug that boosts metabolism in skeletal muscle, improving blood sugar control and fat burning in early studies without reducing appetite or muscle mass. Unlike GLP-1-based drugs such as Ozempic, the candidate acts directly on muscle tissue and has shown good tolerability in an initial clinical trial, according to the study authors.

Researchers report that a protein signal called SLIT3 helps brown fat ramp up heat production by coordinating the growth of blood vessels and sympathetic nerves. In experiments using mouse models and human cells and tissue datasets, the team found SLIT3 is cut into two fragments with distinct roles—one linked to vessel growth and the other to nerve expansion—pointing to possible future obesity-treatment strategies aimed at boosting energy expenditure.

An Ruwaito ta hanyar AI

Researchers at the University of Technology Sydney have created experimental compounds that prompt mitochondria to burn more calories safely. These mild mitochondrial uncouplers could offer a new approach to treating obesity without the deadly risks of past chemicals. The findings, published in Chemical Science, highlight potential benefits for metabolic health and aging.

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi